Alrex® (loteprednol) – First-time generic

Site Logo

Contact our sales team

Provide your contact details below, so one of our product specialists can schedule a call.

Need help or account access? View our support resources or sign in.

* = Required Field
First name
Last name
Email address
Country
Phone
Job Title:
Job function
Job level:
Company
Company type
Solution of interest
Tell us about your business
If you need support, please go to the product support portals.

By submitting the form, you are agreeing to the Optum Terms of Use and Privacy Policy.

SF/GO Parent Program Name_hidden
Product Taxonomy Product Segment_hidden
Product Taxonomy Product Sub Segment_hidden
Product Taxonomy Product Unit_hidden
Product Taxonomy Product Family_hidden
Product PIM Product ID_hidden
ID SF/GO: Campaign ID_hidden
ID SF/GO: Campaign Name_hidden
Person Notes Text Area_hidden
UUID_hidden

Get in touch

Contact our sales team
Connect with us for solutions or services.

Customer sign-in
Access our customer portals.
Optum Provider Portal   Optum Pay All Sign-in Portals

Support and resources
Manage your account, find resources and more.
Payer lists   Enrollment forms   Product Support portals   Claims
Rx Prior Authorization   Join Our Team   All Support

Alrex^® (loteprednol) – First-time generic

February 9, 2024 - Armas launched an AB-rated generic version of Bausch and Lomb’s Alrex (loteprednol) 0.2% ophthalmic suspension.

back to top